330 results on '"A, Barbeau"'
Search Results
2. PCR258 Baseline Demographic and Clinical Characteristics of Patients with Plaque Psoriasis Treated with Brodalumab in the Canadian Real-World Setting: Results from the Care Study
3. PCR28 Utility Values Derived From Canadian Adults With Toenail Onychomycosis With and Without Comorbid Diabetes Mellitus: A Study Using the Health Utilities Index®
4. HPR83 Unequal Access of Innovative Dermatology Products Across Canada
5. RWD76 Real-World Patient Persistence and Compliance: A Comparison of Prostaglandin Analogs Used for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
6. SA33 Demographic Characteristics of Patients Initiating Topical Combination Therapies for Plaque Psoriasis in Canada: A Claims-Based Analysis
7. PCR146 Preferences for Toenail Onychomycosis Treatments Among Canadians With and Without Diabetes Mellitus: A Discrete Choice Experiment
8. EE664 Cost-Effectiveness Analysis of IDP-126, a Topical Triple Therapy, for the Treatment of Acne Vulgaris From the Perspective of Canadian Public Payers
9. HSD8 Real-World Patient Persistence: A Comparison of Prostaglandin Analogs Used for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
10. PCR146 Preferences for Toenail Onychomycosis Treatments Among Canadians With and Without Diabetes Mellitus: A Discrete Choice Experiment
11. PCR28 Utility Values Derived From Canadian Adults With Toenail Onychomycosis With and Without Comorbid Diabetes Mellitus: A Study Using the Health Utilities Index®
12. HPR83 Unequal Access of Innovative Dermatology Products Across Canada
13. RWD76 Real-World Patient Persistence and Compliance: A Comparison of Prostaglandin Analogs Used for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
14. SA33 Demographic Characteristics of Patients Initiating Topical Combination Therapies for Plaque Psoriasis in Canada: A Claims-Based Analysis
15. POSB157 Demographics and Treatment Patterns of Onychomycosis Patients Claiming Efinaconazole: A Canadian Retrospective Claims Analysis Stratified By Diabetes Status
16. HSD8 Real-World Patient Persistence: A Comparison of Prostaglandin Analogs Used for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
17. PSS11 Comparing Patient's Compliance and Persistence on Prostaglandin Analogs Using Real-World Utilization Databases for the Treatment of OPEN-Angle Glaucoma or Ocular Hypertension.
18. PIN61 Switch Patterns Among Patients Claiming Antifungal Therapies for Onychomycosis in Canada
19. EE418 Cost-Effectiveness Analysis of Halobetasol and Tazarotene (DUOBRIITM) Compared to Standard of Care for Adult Patients with Moderate-to-Severe Plaque Psoriasis in Québec
20. POSB157 Demographics and Treatment Patterns of Onychomycosis Patients Claiming Efinaconazole: A Canadian Retrospective Claims Analysis Stratified By Diabetes Status
21. PSS5 Cost per Responder Analysis of Latanoprostene Bunod Compared to Prostaglandin Analogs for OPEN-Angle Glaucoma in Canada
22. PSS2 A CANADIAN NETWORK META-ANALYSIS OF THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
23. PSS11 Comparing Patient's Compliance and Persistence on Prostaglandin Analogs Using Real-World Utilization Databases for the Treatment of OPEN-Angle Glaucoma or Ocular Hypertension
24. PIN61 Switch Patterns Among Patients Claiming Antifungal Therapies for Onychomycosis in Canada
25. PSS5 Cost per Responder Analysis of Latanoprostene Bunod Compared to Prostaglandin Analogs for OPEN-Angle Glaucoma in Canada
26. PSS2 A CANADIAN NETWORK META-ANALYSIS OF THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
27. PSS5 THE COST-EFFECTIVENESS OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A CANADIAN ANALYSIS
28. PDB14 COST-EFFECTIVENESS OF CONTRAVE® IN OBESITY MANAGEMENT IN CANADA
29. PSS3 INDUCTION COST PER RESPONDER OF BRODALUMAB COMPARED WITH OTHER BIOLOGICS APPROVED FOR PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN CANADA
30. PSS5 THE COST-EFFECTIVENESS OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A CANADIAN ANALYSIS
31. PSS2 THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS
32. PSS3 LATANOPROSTENE BUNOD FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION: SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
33. PIN33 COST-EFFECTIVENESS ANALYSIS OF EFINACONAZOLE FOR THE TREATMENT OF MILD TO MODERATE TOENAIL ONYCHOMYCOSIS IN CANADA
34. Cost-Effectivess Analysis of Brodalumab in Moderate-To-Severe Plaque Psoriasis in Canada
35. PDB14 COST-EFFECTIVENESS OF CONTRAVE® IN OBESITY MANAGEMENT IN CANADA
36. PSS3 INDUCTION COST PER RESPONDER OF BRODALUMAB COMPARED WITH OTHER BIOLOGICS APPROVED FOR PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN CANADA
37. PIN33 COST-EFFECTIVENESS ANALYSIS OF EFINACONAZOLE FOR THE TREATMENT OF MILD TO MODERATE TOENAIL ONYCHOMYCOSIS IN CANADA
38. PSS2 THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS
39. PSS3 LATANOPROSTENE BUNOD FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION: SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
40. PSS17 - COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
41. Efficacy of Brodalumab in the Treatment of Moderate-To-Severe Psoriasis: A Network Meta-Analysis
42. Cost-Effectivess Analysis of Brodalumab in Moderate-To-Severe Plaque Psoriasis in Canada
43. Treatment Patterns of Chronic Heart Failure (CHF) In Mexico
44. Secukinumab vs Adalimumab for The Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis At 48 Weeks from A Chilean Perspective
45. Assessing The Burden Of Chronic Heart Failure (Chf) On Patients’ Caregivers In Argentina
46. Applying The Institute For Clinical And Economic Review’s (ICER) Methodology To Canada: An Improved Way To Take Into Consideration Drug Affordability Challenges?
47. Secukinumab Vs. Adalimumab for the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis at 48 Weeks from an Argentinian Perspective
48. PSS17 - COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
49. Efficacy of Brodalumab in the Treatment of Moderate-To-Severe Psoriasis: A Network Meta-Analysis
50. Potential Mortality Reduction with Optimal Usage of Sacubitril/Valsartan Therapy for the Treatment of Heart Failure in Brazil
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.